Group 1: Company Overview and Strategy - The company focuses on traditional Chinese medicine and is expanding into health and rehabilitation sectors, emphasizing a combination of medical care and elderly care [3] - The health industry is a key development area for the company, with plans to integrate rehabilitation, health maintenance, and wellness [3][4] Group 2: Rehabilitation and Wellness Model - The company aims to create a high-end rehabilitation and wellness facility, differentiating itself from traditional nursing homes by offering more than just accommodation [4] - The chosen location for the facility is strategically placed between Yiyang and Changsha, providing convenient access and a pleasant environment [4] Group 3: Medical Partnerships and Resources - The company is targeting partnerships with secondary hospitals (Level II) and is open to collaborations with specialized departments and experts from major hospitals [5] - The company is developing a demonstration base for the cultivation of traditional Chinese medicinal herbs, focusing on resource integration rather than market monopoly [5] Group 4: Financial Investments and Risks - The company has invested over 400 million in the new South Yue Pharmaceutical plant, which has recently passed GMP certification [6] - Investment in Sanxiang Bank is aimed at supplementing profits and providing new financing channels, with funding sourced from internal funds and potential bank credit [6] Group 5: Market Performance and Sales Strategy - The market share of Si Mo Tang is currently 72% in OTC and grassroots medical institutions, while hospitals account for 28% [6] - The company has established a WeChat public account for brand promotion and is considering developing an app for direct sales in the future [6]

证券代码：002412 证券简称：汉森制药 湖南汉森制药股份有限公司 投资者关系活动记录表 编号：2015-001 | --- | --- | --- | |-------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动类别 | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ 其他 | （请文字说明其他活动内容） | | | 大禹资产管理有限公司 ...

Group 1: Company Overview and Strategic Direction - The company is focusing on the cultivation of traditional Chinese medicinal materials, primarily Zhiqiao, to meet raw material demands and respond to government policies [4] - The company aims to establish "Xiang Jiuwai" as a leading brand in the market [4] - Future plans include collaborating with influential hospitals in surrounding cities for health check-ups and rehabilitation services [4] Group 2: Market Challenges and Sales Performance - The sales of Si Mo Tang have not met expectations due to several factors, including a challenging OTC environment, media events affecting consumer perception, and the suspension of basic medicine inclusion in various provinces [6] - In 2014, approximately 70% of Si Mo Tang's revenue came from OTC sales, which has been significantly impacted [6] - Sales in Hunan have remained flat this year, with some progress in market expansion in Xiangnan and Xiangxi regions [6] Group 3: Investment and Financial Planning - The company is gradually advancing its investment in the health industry, with a focus on feasibility studies for medical services [5] - The investment amount for new projects will be determined based on the company's capacity [5] - The company has previously published a feasibility study report on the cultivation of medicinal materials [5] Group 4: Acquisition and Market Positioning - The company continues to prioritize acquisitions as a key strategy, given the lengthy and costly process of developing new traditional Chinese medicines [8] - The integration of Yongzitang's sales has faced challenges, but improvements are being made as stakeholders understand the long-term benefits [7] - Yongzitang's sales were projected to reach 200 million, but this target was not met due to price adjustments and the overall OTC environment [7] Group 5: Regulatory and Compliance Issues - Yongzitang's products have been included in the medical insurance directory in thirteen provinces, with hopes for national coverage [8] - The company is actively working on pricing adjustments and tendering processes to align with market standards [8] - The future handling of the major shareholder's asset, Nanyue Pharmaceutical, remains uncertain as it is undergoing GMP certification [8]

证券代码：002412 证券简称：汉森制药 湖南汉森制药股份有限公司 投资者关系活动记录表 编号：2015-003 | --- | --- | --- | |--------------------|------------------------|----------------------------| | | √ | 特定对象调研 □分析师会议 | | | □ 媒体采访 □业绩说明会 | | | 投资者关系活动类别 | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ 其他 | （请文字说明其他活动内容） | | 参与单位名称及 | 广发资管 | 毛丁丁 | | 人员姓名 | 红塔红土 | 谭权胜 | | | | | | | 彤源投资 | 谷玺 | | | 海通资管 | 刘彬 | | | SMC 基金 | 王帅 | | | 国都证券 | 赵玥 | | | 中信产业基金 | 陈宇 | | | 坚木投资 | 刘晓霞、刘彬阳 | | | 国都资管 | 姚巍 | | | 中欧博瑞 | 汪洋、张宪强 | | | 泰康人寿 | 殷萌萌 | | | 中欧基金 | 龙宇飞 | 1 | --- ...

Group 1: Company Development and Strategy - The future direction of Hansen Health Industry includes standardized planting of traditional Chinese medicinal materials and integration of medical and health services [4] - The company is focusing on investing in unique traditional Chinese medicine formulation enterprises and seeking good hospital platforms, as well as considering retail pharmacy chain investments [4][5] - The company will not abandon its investment plans in women's and children's hospitals, despite current policy restrictions [5] Group 2: Sales and Marketing - The company has shifted from a product-centric division system to a market-oriented marketing channel system, enhancing clarity in responsibilities and stability in organizational structure [5] - The acquisition of Yongzitang was aimed at diversifying product offerings and mitigating risks associated with a limited product range [6] Group 3: Financial Performance and Challenges - The company's 2016 performance forecast is cautious due to increased depreciation, reduced bank interest income, rising marketing expenses, and adverse macroeconomic factors such as national medical insurance cost control and declining tender prices [6] - The company is facing challenges in the bidding process due to declining local tender prices, but maintains a price floor for its products [6][7] Group 4: Investment and Banking - The company is actively involved in the establishment of Sanxiang Bank, which is expected to provide new profit growth points and funding support for future investments [7]

证券代码：002412 证券简称：汉森制药 湖南汉森制药股份有限公司 投资者关系活动记录表 编号：2016-002 | --- | --- | --- | |--------------------|-----------------------------------|----------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动类别 | □ 新闻发布会 □路演活动 □ 现场参观 | | | | □ 其他 | （请文字说明其他活动内容） | | 参与单位名称及 | 吴学贵 | | | 人员姓名 | 周光华 | | | | 黄子生 | | | | 吴丁杰 | | | | 雷志鹏 | | | | 邓彬城 | | | | 张颖国 | | | | 李智雄 | | | | 黄国权 | | | | 陈少仲 | | | | 蔡丽 | | | | 梁亚玲 | | 1 | --- | --- | |-----------------------------|----------------------- ...

Financial Performance - The company's revenue for Q3 2022 was CNY 218,470,759.89, an increase of 0.76% year-on-year, while the revenue for the year-to-date period reached CNY 681,150,652.08, up 3.22% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2022 was CNY 51,192,368.36, representing a growth of 19.45% year-on-year, and the year-to-date net profit was CNY 130,074,008.87, an increase of 14.61%[4] - The basic earnings per share for Q3 2022 was CNY 0.1017, up 19.37% year-on-year, with diluted earnings per share also at CNY 0.1017[4] - Total operating revenue for the period reached ¥681,150,652.08, an increase of 3.7% compared to ¥659,918,134.34 in the previous period[22] - Net profit attributable to shareholders was ¥130,074,008.87, representing a 14.6% increase from ¥113,492,866.04 year-over-year[23] - Basic and diluted earnings per share increased to ¥0.2585 from ¥0.2255, reflecting a growth of 14.0%[24] Assets and Liabilities - Total assets at the end of Q3 2022 amounted to CNY 2,326,803,516.30, reflecting a growth of 10.21% compared to the end of the previous year[4] - The total assets of the company reached ¥2,326,803,516.30, an increase from ¥2,111,282,192.35 at the beginning of the year, reflecting a growth of 10.2%[20] - The company's accounts receivable rose to ¥244,069,859.79, compared to ¥207,401,998.50 at the start of the year, indicating an increase of 17.6%[20] - The total liabilities rose to ¥454,999,569.04, compared to ¥368,989,659.95 in the previous period, marking a 23.3% increase[23] - The total liabilities include accounts payable of ¥37,720,362.29, down from ¥51,440,181.32, indicating a decrease of 26.7%[20] Cash Flow - Cash flow from operating activities showed a net outflow of CNY 99,673,861.60 year-to-date, a significant decrease of 44.28% compared to the same period last year[4] - Cash flow from operating activities decreased to ¥715,181,968.17 from ¥779,328,523.24, a decline of 8.2%[25] - The net cash flow from operating activities for Q3 2022 was ¥99,673,861.60, a decrease of 44.3% compared to ¥178,868,988.40 in Q3 2021[26] - The total cash inflow from operating activities was ¥727,909,881.30, compared to ¥793,862,474.10 in the same quarter last year[26] - The total cash outflow from operating activities was ¥628,236,019.70, slightly higher than ¥614,993,485.70 in Q3 2021[26] Investments and Financing - The net cash flow from investing activities increased by 59.84% year-on-year, primarily due to an increase in cash received from purchasing bank wealth management and structured deposit products[11] - The net cash flow from financing activities increased by 432.43% year-on-year, mainly due to an increase in cash received from bank loans amounting to CNY 20,000,000[13] - Total cash inflow from investment activities was ¥105,725,650.98, significantly higher than ¥9,451,927.51 in the previous year[26] - The net cash flow from investment activities was -¥60,548,911.08, improving from -¥150,779,901.61 in Q3 2021[26] - Cash inflow from financing activities totaled ¥151,504,745.40, up from ¥130,153,195.20 in the same quarter last year[26] - The net cash flow from financing activities was ¥18,628,464.93, a turnaround from -¥5,603,689.48 in Q3 2021[26] Shareholder Information - The company’s total equity attributable to shareholders at the end of Q3 2022 was CNY 1,871,803,947.26, a growth of 7.43% compared to the end of the previous year[4] - The total equity attributable to shareholders increased to ¥1,871,803,947.26, up from ¥1,742,292,532.40, a growth of 7.4%[23] - The total number of common shareholders at the end of the reporting period is 33,824[15] - The largest shareholder, Hainan Hansen Holdings (Limited Partnership), holds 42.13% of the shares, totaling 212,006,189 shares[15] Other Income and Expenses - The company’s other income increased by 208.05% year-on-year, mainly due to a tax reward received from the local government amounting to CNY 2,844,100.00[9] - Research and development expenses for the period were ¥33,008,550.96, compared to ¥26,339,208.61 in the previous period, indicating a 25.4% increase[23] - Other comprehensive income after tax decreased to -¥1,912,591.42 from ¥7,803,735.27, reflecting a significant decline[24] - The total comprehensive income for the period was ¥128,161,417.45, compared to ¥121,296,601.31 in the previous period, an increase of 5.7%[24] Audit Information - The company did not undergo an audit for the Q3 report[28]

证券代码：002412 证券简称：汉森制药 公告编号：2022-026 湖南汉森制药股份有限公司 关于参加 2022 年湖南辖区上市公司投资者 网上集体接待日活动的公告 本公司及全体董事保证公告内容真实、准确和完整，不存在虚假记载、误 导性陈述或者重大遗漏。 为进一步加强与广大投资者的沟通交流，湖南汉森制药股份有限公司（以下 简称"公司"）将参加由中国证券监督管理委员会湖南证监局、湖南省上市公司 协会与深圳市全景网络有限公司联合举办的"湖南辖区上市公司投资者网上接待 日"活动，现将有关事项公告如下： 本次网上接待日活动将采取网络远程的方式举行，投资者可以登录"全景路 演"网站（http://rs.p5w.net），参与本次投资者网上接待日活动，活动时间为 2022 年 09 月 29 日（星期四）下午 15：30 至 17：00。 届时公司董事会秘书、证券事务代表将通过网络在线问答互动的形式，就投 资者关心的问题进行沟通与交流。 欢迎广大投资者积极参与。 | --- | --- | --- | |-------|-------|-------------------------------| | | | 湖南 ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥462,679,892.19, representing a 4.42% increase compared to ¥443,087,312.44 in the same period last year[17]. - The net profit attributable to shareholders was ¥78,881,640.51, an increase of 11.67% from ¥70,635,880.51 in the previous year[18]. - Basic earnings per share rose to ¥0.1568, reflecting an increase of 11.68% from ¥0.1404 in the previous year[18]. - The total profit for the same period was CNY 89.18 million, up 11.59% compared to the previous year[28]. - The company's total revenue for the first half of 2022 was CNY 462.68 million, representing a year-on-year increase of 4.42%[28]. - The company's total profit for the first half of 2022 was CNY 89,176,229.11, compared to CNY 79,911,966.72 in the same period of 2021, indicating a growth of around 11.6%[124]. - The company's total comprehensive income for the first half of 2022 was CNY 80,297,117.33, compared to CNY 69,801,420.66 in the same period of 2021, reflecting an increase of approximately 15%[125]. Cash Flow and Financial Position - The net cash flow from operating activities decreased by 52.68%, amounting to ¥54,750,153.07 compared to ¥115,705,962.98 in the same period last year[18]. - The net cash flow from operating activities decreased to ¥54,750,153.07 in the first half of 2022, down 52.7% from ¥115,705,962.98 in the same period of 2021[130]. - The net increase in cash and cash equivalents was CNY 25,966,831.51, a decline of 66.82% from CNY 78,270,772.81 in the previous year[32]. - The company's cash and cash equivalents increased to ¥116,278,277.21 from ¥90,311,445.70 at the beginning of the year, representing a growth of approximately 29%[116]. - The company's total assets at the end of the reporting period were ¥2,203,980,410.94, a 4.39% increase from ¥2,111,282,192.35 at the end of the previous year[18]. - The total liabilities increased to CNY 381,390,761.21 as of June 30, 2022, compared to CNY 368,989,659.95 at the start of the year, marking an increase of about 3.6%[118]. Investment and R&D - Research and development expenses increased by 29.52% to CNY 23,042,775.48, compared to CNY 17,791,098.85 in the same period last year[32]. - The company has committed to continuous investment in drug research and development, with a focus on the consistency evaluation of generic drugs, despite the high costs and risks involved[60]. - The company plans to enhance its research and development capabilities to innovate new technologies and products[137]. - The company aims to improve operational efficiency through potential mergers and acquisitions in the upcoming fiscal year[142]. Product and Market Strategy - The company's main product, Si Mo Tang oral liquid, is a unique product in the market and has been included in the national medical insurance directory[28]. - The marketing strategy has been optimized to adapt to industry changes, focusing on specialized operations across different market segments[27]. - The company plans to diversify its product offerings to support sustainable profit growth in the future[28]. - The company plans to expand its market presence and invest in new product development to drive future growth[141]. Risk Management and Compliance - The company emphasizes the importance of risk awareness regarding future plans and development strategies[3]. - The company faces risks related to raw material procurement, particularly for traditional Chinese medicine ingredients, which may be affected by environmental factors and resource scarcity[60]. - The company will strengthen quality control measures and adhere to environmental regulations to mitigate production-related risks[61]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[70]. Corporate Governance and Structure - The company has not engaged in any related party transactions during the reporting period[82]. - The company has not reported any significant financial indicators affected by share changes[101]. - The company has five subsidiaries included in the consolidation scope as of June 30, 2022, indicating a stable operational structure[150]. - The financial report was approved by the fifth board of directors on August 26, 2022, ensuring compliance with regulatory standards[150]. Future Outlook - Future guidance indicates a cautious outlook with expected revenue growth of 2.3% for the next half-year[141]. - The company aims to optimize its product structure and actively seek acquisition opportunities to diversify its product offerings and create new profit growth points[61].

Financial Performance - The company's revenue for Q1 2022 was CNY 248,851,389.62, representing a 5.72% increase compared to CNY 235,387,600.31 in the same period last year[3] - Net profit attributable to shareholders was CNY 51,824,070.34, up 13.32% from CNY 45,731,537.24 year-on-year[3] - The total operating revenue for Q1 2022 was CNY 248,851,389.62, an increase of 5.8% compared to CNY 235,387,600.31 in Q1 2021[18] - The net profit for Q1 2022 reached CNY 51,824,070.34, representing a growth of 13.5% from CNY 45,731,537.24 in the same period last year[19] - The total comprehensive income for Q1 2022 was CNY 49,185,657.62, compared to CNY 41,997,646.77 in the same period last year, marking an increase of 17.5%[20] - The company's diluted earnings per share increased by 13.31% to CNY 0.1030 from CNY 0.0909 in the previous year[3] - The basic earnings per share for Q1 2022 was CNY 0.1030, an increase from CNY 0.0909 in Q1 2021[20] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 37.91% to CNY 44,016,378.08, down from CNY 70,886,845.47 in the previous year[3] - The cash inflow from operating activities was CNY 249,825,439.23, compared to CNY 242,374,291.24 in the previous year, indicating a growth of 3.0%[21] - The total cash and cash equivalents at the end of Q1 2022 amounted to ¥90,759,367.83, down from ¥133,986,934.55 at the end of Q1 2021[23] - The company reported a total cash outflow from operating activities of ¥205,809,061.15, which is an increase from ¥171,487,445.77 in Q1 2021[23] - The company reported a decrease in cash and cash equivalents by 98.53%, totaling CNY 1,000,000.00 compared to the previous year[8] Research and Development - R&D expenses increased by 35.74% to CNY 8,598,000.00, primarily due to enhanced investment in the consistency evaluation of isoniazid tablets and iodinated contrast agents[6] - Research and development expenses increased to CNY 8,682,027.43, up 35.7% from CNY 6,396,211.92 in Q1 2021[18] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,132,384,519.04, a 1.00% increase from CNY 2,111,282,192.35 at the end of the previous year[3] - The total current assets are RMB 560,644,902.53, up from RMB 535,410,439.63 at the beginning of the year, reflecting a growth of approximately 4.3%[15] - The accounts receivable increased to RMB 245,321,781.67 from RMB 207,401,998.50, indicating a growth of about 18.3%[15] - The total liabilities decreased to CNY 340,906,329.02 from CNY 368,989,659.95 year-over-year, reflecting a reduction of approximately 7.6%[17] - The company's short-term borrowings decreased to RMB 102,901,468.00 from RMB 131,791,855.05, a reduction of approximately 22%[15] Shareholder Information - The total number of common shareholders at the end of the reporting period is 46,670[10] - The largest shareholder, Hainan Hansen Holdings (Limited Partnership), holds 42.13% of the shares, totaling 212,006,189 shares[10] - The total number of shares held by the top ten unrestricted shareholders includes 212,006,189 shares held by Hainan Hansen Holdings[10] Other Financial Activities - The company completed the registration of business changes and received a new business license on January 8, 2022[12] - The company plans to invest up to RMB 10 million as a limited partner in an industry investment fund with Shenzhen Rongyu Capital Management Co., Ltd.[12] - The company recorded a total of CNY 551,165.57 in non-recurring gains and losses for the reporting period[5] Operating Costs - The total operating costs for Q1 2022 were CNY 199,935,352.92, slightly up from CNY 197,880,670.79 in Q1 2021[18] - The company reported a decrease in sales expenses to CNY 105,570,433.08 from CNY 108,676,129.07 year-over-year, a reduction of 2.0%[18] Audit and Reporting - The company did not conduct an audit for the Q1 2022 report[24] - The report was released by the board of directors on April 28, 2022[25]